Currently, CAR-T therapies target the B-cell maturation antigen (BCMA) for multiple myeloma (MM) and the B-cell antigen CD19 for B-cell leukaemias and lymphomas. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.